CLOs on the Move

Zymeworks

www.zymeworks.com

 
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetricâ„¢ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.zymeworks.com
  • 114 East 4th Avenue Suite 800
    Vancouver, BC CAN V6H 3V9
  • Phone: 604.678.1388

Executives

Name Title Contact Details
Catherine Graham
Vice President of Legal Profile
Jill Scott
Director, Legal Profile

Similar Companies

K Biosciences

K Biosciences is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reichert Analytical Instruments

Reichert Analytical Instruments is a Depew, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.

CELLINK

CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.

Townsend

At Townsend’s Louisiana treatment centers, we care for addiction as a single disease that is typically self-treated with alcohol, drugs, gambling, sex, compulsive overeating, and other substances.